Skip to main content

Advertisement

SpringerLink
Log in

Prevention of recurrent autonomic dysreflexia: a survey of current practice

  • Research Article
  • Published:
Clinical Autonomic Research Aims and scope Submit manuscript

Abstract

Objective

There is a dearth of literature on the treatment of chronic recurrent autonomic dysreflexia (AD), a well-known complication of spinal cord injury that can have life-threatening implications. This study sought to identify clinical practices regarding the treatment of AD, both acute and recurrent, in patients with spinal cord injury (SCI).

Methods

Online survey regarding AD management in SCI composed of 11 questions designed to obtain information on respondent characteristics, AD treatment options, and causes of AD.

Setting

Veterans Administration health care system.

Participants

Veterans Health Administration National SCI Staff Physicians were sent an electronic email to participate in the anonymous web-based survey.

Intervention

None applicable.

Results

The response rate was 52 %. The most commonly prescribed medications for minor and severe acute manifestations of AD were nitrates. For recurrent AD, clonidine was the most commonly prescribed medication.

Interpretation

Anti-hypertensive medications continue to be the mainstay in the management of both acute and chronic recurrent AD. Current literature is lacking in prospective randomized controlled trials investigating the relative efficacy of AD interventions. Evidence-based practice guidelines are necessary to improve clinical care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krassioukov A, Warburton D, Teasell R, Eng J (2009) A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil 37:383–391

    Google Scholar 

  2. Curt A, Nitsche B, Rodic B, Schurch B, Dietz V (1997) Assessment of autonomic dysreflexia in patients with cord injury. J Neurol Neurosurg Psychiatry 62:473–477

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Elliot S, Krassioukov A (2006) Malignant autonomic dysreflexia in spinal cord injured men. Spinal Cord 44:386–392

    Article  Google Scholar 

  4. Karlsson AK (1999) Autonomic Dysreflexia. Spinal Cord. 37:383–391

    Article  CAS  PubMed  Google Scholar 

  5. Braddom R, Rocco J (1991) Autonomic dysreflexia—a survey of current treatment. Am J Phys Med Rehabil 70(5):234–241

    Article  CAS  PubMed  Google Scholar 

  6. Weaver L (2002) What causes autonomic dysreflexia after spinal cord injury? Clin Auton Res 12:424–426

    Article  PubMed  Google Scholar 

  7. Leman S, Sequeira H (2002) Activation of adrenal preganglionic neurons during autonomic dysreflexia in the chronic spinal cord-injured rat. Auton Neurosci 98:94–98

    Article  PubMed  Google Scholar 

  8. Consortium for Spinal Cord Medicine (2002) Acute management of autonomic dysreflexia: adults with spinal cord injury presenting to health care facilities. J Spinal Cord Med 25:S67–S88

    Google Scholar 

  9. Erickson RP (1980) Autonomic hyperreflexia: pathophysiology and medical management. Arch Phys Med Rehab. 61:431–440

    CAS  Google Scholar 

  10. Rabchevsky A, Kitzman P (2011) Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. Neurotherapeutics 8:274–282

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Drug monographs-nitroglycerin. www.mdconsult.com. Accessed 20 September 2014

  12. Grossman E, Messerli FH, Grodzicki T, Kowey P (1996) Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 276(16):1328–1331

    Article  CAS  PubMed  Google Scholar 

  13. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed 20 July 2014

  14. Crassous PA, Denis C, Paris H, Sénard JM (2007) Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. Curr Top Med Chem 7(2):187–194

    Article  CAS  PubMed  Google Scholar 

  15. Drug monographs-prazosin. www.mdconsult.com. Accessed 20 September 2014)

  16. Chancellor MB, Erhard MJ, Hirsch IH, Stass WE Jr (1994) Prospective evaluation of terazosin for treatment of autonomic dysreflexia. J Urol 151:111–113

    CAS  PubMed  Google Scholar 

  17. Luther RR (1989) Terazosin: a new antihypertensive with a favorable effect on lipids. Int J Clin Pharmacol Ther Toxicol 27(7):313–319

    CAS  PubMed  Google Scholar 

  18. Drug monographs-terazosin. www.mdconsult.com. Accessed 01 April 2014)

  19. Dessì-Fulgheri P, Bandiera F, Rubattu S et al (1987) Comparison of sublingual and oral captopril in hypertension. Clin Exp Hypertens 9(2–3):593–597

    Google Scholar 

  20. Esmail Z, Shalansky KF, Sunderji R et al (2002) Evaluation of captopril for the management of hypertension in autonomic dysreflexia: a pilot study. Arch Phys Med Rehabil 83(5):604–608

    Article  PubMed  Google Scholar 

  21. Braddom RL, Johnson EW (1969) Mecamylamine in control of hyperreflexia. Arch Phys Med Rehabil 50:448–453

    CAS  PubMed  Google Scholar 

  22. Frishman WH (2009) Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 4:287–308

    Article  Google Scholar 

  23. Hall PA, Young JV (1983) Autonomic hyperreflexia in spinal cord injured patients: trigger mechanism-dressing changes of pressure sores. J Trauma 23:1074–1075

    Article  CAS  PubMed  Google Scholar 

  24. Wright KD, Agre JC, Wilson BC, Theologides A (1986) Autonomic dysreflexia in a paraplegic man with catecholamine secreting neuroblastoma. Arch Phys Med Rehabil 67:566–567

    CAS  PubMed  Google Scholar 

  25. Vaidyanathan S, Soni BM, Sett P, Watt JW, Oo T, Bingley J (1998) Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and pediatric spinal cord injury patients manifesting recurrent dysreflexic episodes. Spinal Cord 36:761–770

    Article  CAS  PubMed  Google Scholar 

  26. Krum H, Louis WJ, Brown DJ, Howes LG (1992) A study of the alpha-1 adrenoreceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res 2(2):83–88

    Article  CAS  PubMed  Google Scholar 

  27. Lindan R, Leffler E, Kedia K (1985) A comparison of the efficacy of an alpha 1 adrenergic blocker in the slow calcium channel blocker in the control of autonomic dysreflexia. Paraplegia 23:34–38

    Article  CAS  PubMed  Google Scholar 

  28. McGuire EJ, Wagner FM, Weiss RM (1977) Treatment of autonomic dysreflexia. J Urol 118:70–72

    Google Scholar 

  29. Sizemore GW, Winternitz WW (1970) Autonomic hyper-reflexia—suppression with alpha-adrenergic blocking agents. N Engl J Med 282(14):795

    Article  CAS  PubMed  Google Scholar 

  30. Shessel FS, Carrion HM, Politano VA (1978) Phenoxybenzamine and sweating in the spinal cord injury patient. J Urol 120(1):60–61

    CAS  PubMed  Google Scholar 

  31. Guyton AC, Hall JE (2000) Textbook of medical physiology. W.B. Saunders Company, Philadelphia

    Google Scholar 

  32. Scott MB, Morrow JW (1978) Phenoxybenzamine in neurogenic bladder dysfunction after spinal cord injury. J Urol 199:483–484

    Google Scholar 

  33. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922

    CAS  PubMed  Google Scholar 

  34. Gamé X, Castel-Lacanal E, Bentaleb Y et al (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53(3):613–618 Epub 2007 Aug 28

    Article  PubMed  Google Scholar 

  35. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172:240–243

    Article  CAS  PubMed  Google Scholar 

  36. MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ (2007) Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal Cord 45(8):535–541 Epub 2007 Apr 24

    Article  CAS  PubMed  Google Scholar 

  37. Giannantoni A, Di Stasi SM, Stephen RL et al (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167(4):1710–1714

    Article  CAS  PubMed  Google Scholar 

  38. Igawa Y, Satoh T, Mizusawa H et al (2003) The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. BJU Int 91(7):637–641

    Article  CAS  PubMed  Google Scholar 

  39. Barton CH, Khonsari F, Vaziri ND, Byrne C, Gordon S, Friis R (1986) The effect of modified transurethral sphincterotomy on autonomic dysreflexia. J Urol 135(1):83–85

    CAS  PubMed  Google Scholar 

  40. Perkash I (2007) Transurethral sphincterotomy provides significant relief in autonomic dysreflexia in spinal cord injured male patients: long-term followup results. J Urol 177(3):1026–1029

    Article  PubMed  Google Scholar 

  41. Ricottone AR, Pranikoff K, Steinmetz JR, Constantino G (1995) Long-term follow-up of sphincterotomy in the treatment of autonomic dysreflexia. Neurourol Urodyn 14(1):43–46

    Article  CAS  PubMed  Google Scholar 

  42. Teichman JM, Harris JM, Currie DM, Barber DB (1998) Malone antegrade continence enema for adults with neurogenic bowel disease. J Urol 160(4):1278–1281

    Article  CAS  PubMed  Google Scholar 

  43. Hohenfellner M, Pannek J, Botel U (2001) Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. Urology 58:28–32

    Article  CAS  PubMed  Google Scholar 

  44. Pannek J, Göcking K, Bersc U (2010) Sacral rhizotomy: a salvage procedure in a patient with autonomic dysreflexia. Spinal Cord 48:347–348

    Article  CAS  PubMed  Google Scholar 

  45. Kofler M, Poustka K, Saltuari L (2009) Intrathecal baclofen for autonomic instability due to spinal cord injury. Auton Neurosci 146:106–110

    Article  CAS  PubMed  Google Scholar 

  46. Creasey GH, Grill JH, Korsten M et al (2001) Implanted Neuroprosthesis Research Group: an implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil 82:1512–1519

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University, Richmond, USA

    Deborah Caruso, David Gater & Christopher Harnish

  2. Department of Veterans Affairs, Hunter Holmes McGuire Medical Center, 1201 Broad Rock Boulevard, Richmond, VA, 23249, USA

    Deborah Caruso, David Gater & Christopher Harnish

Authors
  1. Deborah Caruso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Gater
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Harnish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah Caruso.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caruso, D., Gater, D. & Harnish, C. Prevention of recurrent autonomic dysreflexia: a survey of current practice. Clin Auton Res 25, 293–300 (2015). https://doi.org/10.1007/s10286-015-0303-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10286-015-0303-0

Keywords

Search

Navigation